Regentis Biomaterials Ltd.

RGNT · NYSE · Healthcare / Medical Instruments & Supplies

1.23USD-0.02 (-1.60%)

Price History

Full chart

Market Stats

Previous Close1.25

Open1.24

Day Range1.22 – 1.29

52-Week Range1.23 – 9.40

Volume23.15K

Market Cap13.91M

P/E (TTM)0.00

Forward P/E0.00

EPS-23.94

Dividend Yield0.00%

50-Day Avg1.99

200-Day Avg3.59

About

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.

Company Details

SectorHealthcare
IndustryMedical Instruments & Supplies
CEODr. Ehud Geller Ph.D.
Headquarters60, Medinat Hayehudim, Herzliya, Israel, 4676652, USA
Websitehttps://www.regentis.co.il

Leadership

Dr. Ehud Geller Ph.D.CEO & Executive Chairman
Mr. Arie Gordashnikov CPAChief Accounting Officer · b. 1984
Dr. Dror Seliktar Ph.D.Co-Founder & Chief Scientific Officer
Mr. Ori GonCFO & Chief Business Officer · b. 1982
Dr. Galit Reske Ph.D.Chief Medical Officer · b. 1972

Financials

Income Statement

Currency: USD	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	0	0	0	0
Operating Income	-1.41M	-1.93M	932.00K	-8.62M
EBITDA	-1.45M	-3.96M	4.97M	-13.32M
Net Income	-1.45M	-4.13M	4.80M	-13.65M
R&D	971.00K	806.00K	1.64M	331.00K
Interest Expense	0	173.00K	171.00K	324.00K

Balance Sheet

Currency: USD	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	1.72M	360.00K	482.00K	7.62M
Total Liabilities	43.78M	46.27M	41.59M	2.87M
Total Equity	-42.06M	-45.91M	-41.10M	4.74M
Cash	1.24M	345.00K	229.00K	7.38M
Net Debt	5.23M	7.27M	4.72M	-

Cash Flow

Currency: USD	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-1.50M	-1.22M	-641.00K	-1.38M
Financing Cash Flow	0	325.00K	525.00K	8.52M
Capital Expenditure	0	0	0	0
Free Cash Flow	-1.50M	-1.22M	-641.00K	-1.38M
FCF to OCF	100.00%	100.00%	100.00%	100.00%

Key Statistics & Ratios

Market Cap13.91M

Enterprise Value5.83M

Trailing P/E0.00

Forward P/E0.00

Price / Sales0.00

Price / Book1.92

EPS-23.94

Book Value0.916

Revenue (TTM)0

Gross Profit (TTM)0

Profit Margin0.00%

Operating Margin0.00%

Return on Equity0.00%

Return on Assets-113.59%

Shares Outstanding7.02M

Shares Float4.26M

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%